Journal of Microbiology and Biotechnology

The Korean Society for Microbiology and Biotechnology (한국미생물·생명공학회)
권호 표지

Analysis of In Vivo Interaction of HCV NS3 Protein and Specific RNA Aptamer with Yeast Three-Hybrid System

  • HWANG BYOUNGHOON (Department of Molecular Biology, Institute of Nanosensor and Biotechnology, Dankook University) ;
  • LEE SEONG-WOOK (Department of Molecular Biology, Institute of Nanosensor and Biotechnology, Dankook University)
  • Published : 2005.06.01
Download PDF
⟨ Previous Next ⟩

Abstract

We have previously isolated specific RNA aptamers with high affinity against the helicase domain of hepatitis C virus (HCV) nonstructural protein 3 (NS3). The RNA aptamers competitively and efficiently inhibited the helicase activity, partially impeding HCV replicon replication in human hepatocarcinoma cells. In this study, the RNA aptamers were tested for binding to the HCV NS3 proteins in eukaryotic cells, using a yeast three-hybrid system. The aptamers were then recognized by the HCV NS3 proteins when expressed in the cells, while the antisense sequences of the aptamers were not. These results suggest that the in vitro selected RNA aptamers can also specifically bind to the target proteins in vivo. Consequently, they could be potentially utilized as anti-HCV lead compounds.

Keywords

References

  1. Baek, C.-H. and K.-S. Kim. 2003. lacz- and aph-based reporter vectors for in vivo expression technology. J. Microbiol. Biotechnol. 13: 872-880
  2. Biroccio, A., J. Hamm, I. Incitti, R. De Francesco, and L. Tomei. 2002. Selection of RNA aptamers that are specific and high-affinity ligands of the hepatitis C virus RNA-dependent RNA polymerase. J. Virol. 76: 3688-3696 https://doi.org/10.1128/JVI.76.8.3688-3696.2002
  3. Cassiday, L. and L. J. Maher, III. 2001. In vivo recognition of an RNA aptamer by its transcription factor target. Biochemistry 40: 2433-2438 https://doi.org/10.1021/bi002376v
  4. Ellington, A. D. and J. W. Szostak. 1990. In vitro selection of RNA molecules that bind specific ligands. Nature 346: 818-822 https://doi.org/10.1038/346818a0
  5. Fried, M. W., M. L. Shiffman, K. R. Reddy, C. Smith, G. Marinos, F. L. Jr. Goncales, D. Haussinger, M. Diago, G. Carosi, D. Dhumeaux, A. Craxi, A. Lin, J. Hoffman, and J. Yu. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347: 975-982 https://doi.org/10.1056/NEJMoa020047
  6. Fukuda, K., D. Vishnuvardhan, S. Sekiya, J. Hwang, N. Kakiuchi, K. Taira, K. Shimotohno, P. K. Kumar, and S. Nishikawa. 2000. Isolation and characterization of RNA aptamers specific for the hepatitis C virus non structural protein 3 protease. Eur. J. Biochem. 267: 3685-3694 https://doi.org/10.1046/j.1432-1327.2000.01400.x
  7. Hugle, T. and A. Cerny. 2003. Current therapy and new molecular approaches to antiviral treatment and prevention of hepatitis C. Rev. Med. Virol. 13: 361-371 https://doi.org/10.1002/rmv.397
  8. Hwang, B., J. S. Cho, H. J. Yeo, J.-H. Kim, K. M. Chung, K. Han, S. K. Jang, and S.-W. Lee. 2004. Isolation of specific and high-affinity RNA aptamers against NS3 helicase domain of hepatitis C virus. RNA 10: 1277-1290 https://doi.org/10.1261/rna.7100904
  9. Jaeger, S., G. Eriani, and F. Martin. 2004. Results and prospects of the yeast three-hybrid system. FEBS Lett. 556: 7-12 https://doi.org/10.1016/S0014-5793(03)01434-0
  10. Klausner, R. D., T. A. Rouault, and J. B. Harford. 1993. Regulating the fate of mRNA: The control of cellular iron metabolism. Cell 72: 19-28 https://doi.org/10.1016/0092-8674(93)90046-S
  11. Kumar, P. K., K. Machida, P. T. Urvil, N. Kakiuchi, D. Vishnuvardhan, K. Shimotohno, K. Taira, and S. Nishikawa, 1997. Isolation of RNA aptamers specific to the NS3 protein of hepatitis C virus from a pool of completely random RNA. Virology 237: 270-282 https://doi.org/10.1006/viro.1997.8773
  12. Kwong, A. D., J. L. Kim, and C. Lin. 2000. Structure and function of hepatitis C virus NS3 helicase. Curr. Top. Microbiol. Immunol. 242: 171-196
  13. Lauer, G. M. and B. D. Walker. 2001. Hepatitis C virus infection. N. Engl. J. Med. 345: 41-52 https://doi.org/10.1056/NEJM200107053450107
  14. Penin, F., J. Dubuisson, F. Rey, D. Moradpour, and J.-M. Pawlotsky. 2004. Structural biology of hepatitis C virus. Hepatology 39: 5-19 https://doi.org/10.1002/hep.20032
  15. SenGupta, D. J., B. Zhang, B. Kraemer, P. Pochart, S. Fields, and M. Wickens. 1996. A three-hybrid system to detect RNA-protein interactions in vivo. Proc. Natl. Acad. Sci. USA 93: 8496-8501
  16. Sullenger, B. A. and E. Gilboa. 2002. Emerging clinical applications of RNA. Nature 418: 252-258 https://doi.org/10.1038/418252a
  17. Tuerk, C. and L. Gold. 1990. Systematic evolution ofligands by exponential enrichment: RNA Iigands to bacteriophage T4 DNA polymerase. Science 249: 505-510 https://doi.org/10.1126/science.2200121
  18. Urvil, P. T., N. Kakiuchi, D.-M. Zhou, K. Shimotohno, P. K. R. Kumar, and S. Nishikawa. 1997. Selection of RNA aptamers that bind specifically to the NS3 protease of hepatitis C virus. Eur. J. Biochem. 248: 130-138 https://doi.org/10.1111/j.1432-1033.1997.t01-1-00130.x
  19. Vo, N. V., J. W. Oh, and M. M. Lai. 2003. Identification of RNA Iigands that bind hepatitis C virus polymerase selectively and inhibit its RNA synthesis from the natural viral RNA templates. Virology 307: 301-316 https://doi.org/10.1016/S0042-6822(02)00095-8
  20. Zuker, M. 2003. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 31: 3406-3415 https://doi.org/10.1093/nar/gkg595